Publications:  Mrs Charlotte Ackerman

Hall PE, Shepherd STC, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S et al.(2020). Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. European Urology Focus vol. 6, (5) 999-1005.

Powles T, Gómez de Liaño A, Ackerman C(2017). Reply to Pontus Eriksson, Gottfrid Sjödahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed: Protein Expression to Predict Outcome to Targeted Therapy in Bladder Cancer: Too Little, Too Late?. European Urology vol. 72, (5) e137-e138.

Schmid P, Blackhall F, Muthukumar D, Lester J, Khan S, Adams J, Illsley M, Macgregor C et al.(2017). LBA53 A phase II, randomised, open-label study of gemcitabine/carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide apatorsen (OGX-427) in advanced squamous cell lung cancers. Annals of Oncology vol. 28,

Shepherd STC, Hall P, Brown JE, Larkin JMG, Jones RJ, Ralph C, Hawkins RE, Chowdhury S et al. (2017). Can dynamic changes in prognostic markers predict survival in patients receiving VEGF-targeted therapy in clear cell renal cell carcinoma?. Journal of Clinical Oncology. vol. 35, e16061-e16061.

Ackerman C, Mariathasan S, Nickles D, Gomez De Liano Lista A, Wimalasingham AG, Szabados B, Powles T (2017). Molecular subtyping of metastatic urothelial bladder cancer. Journal of Clinical Oncology. vol. 35, 326-326.

Powles T, Huddart RA, Elliott T, Sarker S-J, Ackerman C, Jones R, Hussain S, Crabb S et al.(2017). Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. J Clin Oncol vol. 35, (1) 48-55.

Powles THOMAS, Huddart RA, Elliott T, SARKER S-J, Ackerman CHARLOTTE, Jones R, Hussaine S, Crabb S et al.(2016). A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients. Journal of Clinical Oncology

Powles T, Sarwar N, Stockdale A, Sarker S-J, Boleti E, Protheroe A, Jones R, Chowdhury S et al.(2016). Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. JAMA Oncology vol. 2, (10) 1303-1309.

Powles T, Brown J, Larkin J, Jones R, Ralph C, Hawkins R, Chowdhury S, Boleti E et al.(2016). A randomized, double-blind phase II study evaluating cediranib versus cediranib and saracatinib in patients with relapsed metastatic clear-cell renal cancer (COSAK). Annals of Oncology vol. 27, (5) 880-886.

Powles T, Hussain SA, Protheroe A, Birtle A, Chakraborti PR, Huddart R, Jagdev S, Bahl A et al. (2016). PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours. Journal of Clinical Oncology. vol. 34, 430-430.

Powles T, Kayani I, Blank CU, Chowdhury S, Horenblas S, Sarwar N, Nathan PD, Boleti E et al.(2010). The safety and efficacy of sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Journal of Clinical Oncology vol. 28, (15_suppl) 4603-4603.